September 20, 2014 7:02 PM ET

Pharmaceuticals

Company Overview of Ribapharm Inc.

Company Overview

Ribapharm Inc. was acquired by Valeant Pharmaceuticals International. Ribapharm, Inc. engages in the development, acquisition, and commercialization of products for the treatment of diseases principally in the antiviral and anticancer areas. The company's focuses its research and development program on hepatitis C, hepatitis B, cancer, and HIV/AIDS. The company’s primary product is Ribavirin, an antiviral drug that was licensed to Schering-Plough, Ltd. and F. Hoffmann-La Roche, Ltd. (Roche) for the treatment of chronic hepatitis C in combination with Schering-Plough's interferon alfa-2b or Roche’s pegylated interferon alfa-2b in the United States, the European Union, Japan, and other countri...

3300 Hyland Avenue

Costa Mesa, CA 92626

United States

Founded in 2000

139 Employees

Phone:

714-427-6236

Fax:

714-641-7223

Key Executives for Ribapharm Inc.

Ribapharm Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Organics L.L.C. United States
KCI International, Inc. United States
Mutual Pharmaceutical Company, Inc. United States
Endo Pharmaceuticals Colorado LLC United States
Tioga Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ribapharm Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.